| STATHMIN — Stathmin-1 Protein | |
|---|---|
| Protein Name | Stathmin-1 Protein |
| Gene | STATHMIN |
| UniProt ID | P16949 |
| PDB IDs | 1CK4, 1IAI, 1KS5 |
| Molecular Weight | 17 kDa (143 amino acids) |
| Subcellular Localization | Cytoplasm, Cytoskeleton |
| Protein Family | Stathmin family (SCG10, SCLIP, RB3) |
| Brain Expression | High in hippocampus, cortex, cerebellum |
Stathmin-1 (also known as oncoprotein 18, OP18) is a microtubule-destabilizing phosphoprotein that plays critical roles in regulating microtubule dynamics, neuronal development, and synaptic plasticity[1]. It is highly expressed in developing neurons and continues to be expressed in adult brain regions involved in learning and memory, including the hippocampus and cerebral cortex[2]. Stathmin-1 has been implicated in multiple neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD), making it a potential therapeutic target[3].
Stathmin-1 is a 143-amino acid protein with a modular structure:
Stathmin-1 is extensively regulated by phosphorylation:
| Site | Kinase | Functional Effect |
|---|---|---|
| Ser16 | PKA, CaMKII | Major regulatory site |
| Ser25 | MAPK, CDK1 | Cell cycle regulation |
| Ser38 | PKA, PKC | Microtubule destabilization |
| Ser63 | PKA, MST1 | Conformational change |
Phosphorylation at these sites reduces stathmin's microtubule-destabilizing activity, while dephosphorylation activates it[4].
Stathmin-1 is a potent microtubule-destabilizing protein that promotes tubulin dimer release and prevents microtubule polymerization[5]:
In the nervous system, stathmin-1 plays several critical roles:
Stathmin-1 shows region-specific expression:
Stathmin-1 dysregulation contributes to AD pathogenesis through multiple mechanisms[6]:
Studies show elevated stathmin-1 expression in AD brain tissue, particularly in regions vulnerable to neurofibrillary tangle formation[7].
In PD, stathmin-1 affects dopaminergic neuron survival[8]:
Stathmin-1 contributes to motor neuron degeneration in ALS[9]:
In HD, stathmin-1 dysfunction affects striatal neuron survival[10]:
Stathmin-1 is an attractive therapeutic target:
Stathmin-1 in cerebrospinal fluid (CSF) may serve as:
Cassimeris L, Stathmin (2002). International Journal of Cancer. ↩︎
Peschel N et al., Stathmin in neuronal development (2009). Neuroscience. ↩︎
Zhang M et al., Stathmin in neurodegeneration (2021). Molecular Neurobiology. ↩︎
Gradwell D et al., Stathmin phosphorylation kinetics (2020). Journal of Biological Chemistry. ↩︎
Jourdain L et al., Stathmin-tubulin interaction (1997). Cell. ↩︎
Sayas CL et al., Stathmin in Alzheimer's disease (2019). Journal of Neurochemistry. ↩︎
Liang Z et al., Stathmin expression in AD brain (2020). Neurobiology of Aging. ↩︎
Kwon Y et al., Stathmin in Parkinson's disease (2021). Molecular Neurobiology. ↩︎
Ma B et al., Stathmin in Huntington's disease (2021). Neurobiology of Aging. ↩︎